Related references
Note: Only part of the references are listed.EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
T. Kumai et al.
BRITISH JOURNAL OF CANCER (2013)
MHC Class I-Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia
Mark Cobbold et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Acetylation Directs Survivin Nuclear Localization to Repress STAT3 Oncogenic Activity
Haijuan Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Structural Basis for the Presentation of Tumor-Associated MHC Class II-Restricted Phosphopeptides to CD4+ T Cells
Yili Li et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
p53 post-translational modification: deregulated in tumorigenesis
Chao Dai et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Post-translationally modified T cell epitopes: immune recognition and immunotherapy
Jan Petersen et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2009)
Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy
Florence R. Depontieu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
Chunaram Choudhary et al.
SCIENCE (2009)
Lysine acetylation: Codified crosstalk with other posttranslational modifications
Xiang-Jiao Yang et al.
MOLECULAR CELL (2008)
An epigenetic vaccine model active in the prevention and treatment of melanoma
A. Nazmul H. Khan et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Functions of Site-Specific Histone Acetylation and Deacetylation
Mona D. Shahbazian et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2007)
Histone acetyltransferase complexes: one size doesn't fit all
Kenneth K. Lee et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy
Angela L. Zarling et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Posttranslational protein modifications - Current implications for cancer detection, prevention, and therapeutics
Karl E. Krueger et al.
MOLECULAR & CELLULAR PROTEOMICS (2006)
Post-translational modifications of naturally processed MHC-binding epitopes
VH Engelhard et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Decoding Tat:: the biology of HIV Tat posttranslational modifications
C Hetzer et al.
MICROBES AND INFECTION (2005)
The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60
JH Patel et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Post-translational modifications of self antigens: implications for autoimmunity
SM Anderton
CURRENT OPINION IN IMMUNOLOGY (2004)
Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase
VO Melnikova et al.
ONCOGENE (2003)
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence
E Langley et al.
EMBO JOURNAL (2002)
Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
RW Johnstone
NATURE REVIEWS DRUG DISCOVERY (2002)
Distinct pattern of p53 phosphorylation in human tumors
T Minamoto et al.
ONCOGENE (2001)
Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo
AL Zarling et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors
WJ Magner et al.
JOURNAL OF IMMUNOLOGY (2000)
Atmospheric carbon dioxide concentrations over the past 60 million years
PN Pearson et al.
NATURE (2000)
An N-acetylated natural ligand of human histocompatibility leukocyte antigen (HLA)-B39:: Classical major histocompatibility complex class I proteins bind peptides with a blocked NH2 terminus in vivo
J Yagüe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)